



# MIT-TSE Health Economics Conference

UNIVERSAL HEALTH CARE  
FINANCING OF PHARMACEUTICAL  
INNOVATION

POSTPONED

MIT Bartos Theater  
April 30, 2020  
8:30 - 17:00

© Rawpixel.com / stock.adobe.com

# MIT-TSE

## Health Economics Conference

---

***DATE TO BE CONFIRMED***

Universal health care

Financing of pharmaceutical innovation

### **ORGANIZERS**

Amy Finkelstein (MIT Economics)

Jean Tirole (TSE- visiting MIT)

Pierre Dubois (TSE- visiting Harvard)

---

### **VENUE**

MIT

Building E15, Bartos Theater

20 Ames Street, Cambridge, MA 02142, USA

---

### **CONTACT**

Eve Sejalon [eve.sejalon@tse-fr.eu](mailto:eve.sejalon@tse-fr.eu)

Tiffany Naylor [tiffany.naylor@tse-fr.eu](mailto:tiffany.naylor@tse-fr.eu)

---

## 8:30–8:40: Welcome words

**Jean Tirole** (Toulouse School of Economics – TSE, visiting MIT).

## Universal health care

### 8:40–10:10: Comparative health care systems

Moderator: **James Hammitt** (TH Chan Harvard School of Public Health – TSE)

**Amy Finkelstein** (MIT Economics) ▶ “Facts and Fallacies: Rethinking US Healthcare”

**Philippe Choné** (CREST Paris) ▶ “Health Care Provision in France: Overview and Policy Discussions”

**Jonathan Pearson-Stuttard** (Imperial College London, School of Public Health) ▶ “The future of healthcare – Shifting populations from illness to health”

10:10–10:25: Coffee break

### 10:25–12:15: New business models for drug pricing

Moderator: **Paul Joskow** (MIT Economics)

**Amitabh Chandra** (Harvard Kennedy School) ▶ “Discrimination in Prescription Markets”

**Maria Polyakova** (Stanford University School of Medicine) ▶ “Subsidizing Privately-Provided Insurance: Challenges of Market Design”

**Pierre Dubois** (TSE) ▶ “Reference Pricing”

**Michael Kremer** (Harvard Economics) ▶ “Advanced Market Commitments”

12:15–13:00: Lunch

## Financing of pharmaceutical innovation

### 13:00–14:50: Challenges for the innovation process

Moderator: **Pierre Azoulay** (MIT Sloan School of Management)

**Andrew Lo** (MIT Sloan School of Management) ▶ “The Challenges and Opportunities in the Financing of Rare Disease Therapeutics”

**Johannes Fruehauf** (Lab Central) ▶ “TBA”

**Peter Kolchinsky** (RA Capital Management) ▶ “The Great American Drug Deal”

**Ajit Singh** (Artiman Management) ▶ “Challenges for the innovation process”

14:50–15:05: Coffee break

### 15:05–17:00: A new industrial policy for drugs?

Moderator: **Bernard Malfroy** (MindSet Rx, Inc)

**Danielle Li** (MIT Sloan School of Management) ▶ “Missing Novelty in Drug Development”

**Jon Gruber** (MIT Economics) ▶ “Jump-Starting America”

**Philippe Sauvage** (Sanofi Genzyme) ▶ “TBA”

**Jean Tirole** (TSE) ▶ “Incentivizing Industrial Policy”

Each session will be followed by a 20-minute period for questions and discussion.